Meets strict flame-retardant compliance

They support compliance with regulatory standards without compromising performance and provide an alternative to brominated polymers for applications such as housings for appliances.  

Mevopur™ Healthcare Colorants and Functional Additives: formulations pre-tested to support compliance with regulatory requirements, such as USP Class VI, ISO 10993, EP3.1, USP661.1, and ICH Q3D and manufactured across a global network of ISO 13485-certified facilities or under GMP certifications.

AVIENT SOLUTION MEDICAL DEVICE MANUFACTURER C O M P R E S S I O N C O N T R O L L E R H O U S I N G G R I P • Good adhesion to PCTG • Comfortable grip combined with ergonomics • Medical regulation compliance • Provided a medical-grade TPE with excellent bonding to PCTG and good chemical resistance • Improved ergonomics and aesthetics with a soft- touch material • Met medical regulation compliance: FDA21 CFR 177.2600 • Delivered good colorability to ensure a stable esthetic KEY REQUIREMENTS OVERMOLDING + REGULATORY SUPPORT LEARN MORE Versollan Thermoplastic Elastomers Copyright © 2024, Avient Corporation.

Cosmetic packaging manufacturer COSMETIC PACKAGING MANUFACTURER L I P G L O S S T U B E T I P • Excellent clarity and high fluidity • FDA thermoplastic elastomer • Overmolds to PE as good sealing performance • Met customer’s design requirements, such as a skin-like feel • Offered transparent appearance • Met FDA 21 compliance • Overmolded onto PE compared with silicone OnFlex Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION SOFT TOUCH + FDA COMPLIANCE LEARN MORE Copyright © 2024, Avient Corporation.

SYRINGE MANUFACTURING D I S P O S A B L E S Y R I N G E T I P C A P • Excellent sealing and resealing performance • No DEHP or natural rubber latex added during processing • Can be sterilized by EtO • Compliance with ISO 10993-4&5, USP Class VI Dynaflex™ Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION COMPLIANCE + EASY PROCESSING Copyright © 2022, Avient Corporation.

H E A LT H C A R E D E V I C E M A N U FAC T U R E R W E B K N E E B R A C E • Good bonding to polypropylene (PP) • Flexible and soft-touch feel • Skin contact, general FDA compliance • Good tensile strength and resilience • Excellent colorability • Offered material that passed the required FDA regulations • Provided high elasticity memory and ultra soft tactile finish to meet the comfort and pleasant surface feeling requirements • Delivered TPE with easy and stable processing and colorability DynaflexTM Thermoplastics Elastomer KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION COMPLIANCE + SOFT TOUCH LEARN MORE Copyright © 2021, Avient Corporation.

MAM L E A R N T O D R I N K ™ C U P • Compliance with EU fatty food contact regulations* • Soft, gentle feel • Non-BPA, non-phthalate • Great colorability • Provided customized solution to comply with Europe’s fatty food contact requirements and application needs • Enhanced customer appeal with a soft, durable and custom-colored solution Versaflex™ FFC Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT? AVIENT SOLUTION MEETS FATTY FOOD COMPLIANCE LEARN MORE* Limitations may apply – check with Avient for more information Copyright © 2020, Avient Corporation.

KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below. It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.

Using our “global reach with a local touch” model to win share and new business 3. All Rights Reserved 2025 9 Regional manufacturing capabilities and supply chains help us serve our customers locally Global reach with a local touch Sales exposure $100M ~3%LESSTHAN Raw materials exposure $100M ~7.5%LESSTHAN Tariff exposure 2025 guidance Copyright © . Three Months Ended March 31, 2025 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) $ EPS(1) Net (loss) income attributable to Avient common shareholders $ (20.2) $ (0.22) $ 49.4 $ 0.54 Special items, after-tax 75.7 0.82 5.5 0.06 Amortization expense, after-tax 14.5 0.16 14.9 0.16 Adjusted net income / EPS $ 70.0 $ 0.76 $ 69.8 $ 0.76 (1) Per share amounts may not recalculate from figures presented herein due to rounding Three Months Ended March 31, Reconciliation to EBITDA and Adjusted EBITDA: 2025 2024 Net (loss) income – GAAP $ (19.9) $ 49.7 Income tax (benefit) expense (6.7) 16.8 Interest expense, net 26.9 26.6 Depreciation & amortization 45.3 44.3 EBITDA $ 45.6 $ 137.4 Special items, before tax 101.2 6.2 Interest expense included in special items (1.7) — Depreciation & amortization included in special items (0.4) (0.5) Adjusted EBITDA $ 144.7 $ 143.1 Adjusted EBITDA as a percent of sales 17.5 % 17.3 % 1 Three Months Ended March 31, 2025 2024 Sales: Color, Additives and Inks $ 519.7 $ 515.3 Specialty Engineered Materials 308.4 314.4 Corporate (1.5) (0.7) Sales $ 826.6 $ 829.0 Operating income: Color, Additives and Inks $ 78.6 $ 74.8 Specialty Engineered Materials 47.1 53.4 Corporate (125.0) (34.2) Operating income $ 0.7 $ 94.0 Depreciation & amortization: Color, Additives and Inks $ 21.7 $ 21.9 Specialty Engineered Materials 21.5 19.6 Corporate 2.1 2.8 Depreciation & amortization $ 45.3 $ 44.3 Earnings before interest, taxes, depreciation and amortization (EBITDA): Color, Additives and Inks $ 100.3 $ 96.7 Specialty Engineered Materials 68.6 73.0 Corporate (122.9) (31.4) Other expense, net (0.4) (0.9) EBITDA $ 45.6 $ 137.4 Special items, before tax 101.2 6.2 Interest expense included in special items (1.7) — Depreciation & amortization included in special items (0.4) (0.5) Adjusted EBITDA $ 144.7 $ 143.1 Adjusted EBITDA as a percent of sales: Color, Additives and Inks 19.3 % 18.8 % Specialty Engineered Materials 22.2 % 23.2 % Reconciliation to EBITDA and Adjusted EBITDA: Year Ended December 31, 2024 Net income – GAAP $ 170.7 Income tax expense 54.1 Interest expense 105.6 Depreciation & amortization 179.7 EBITDA $ 510.1 Special items, before tax 20.1 Interest expense included in special items (2.3) Depreciation & amortization included in special items (1.5) Adjusted EBITDA $ 526.4 Adjusted EBITDA as a percent of sales 16.2 % 2 Three Months Ended March 31, 2023 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income from continuing operations attributable to Avient common shareholders $ 20.8 $ 0.23 Special items, after tax 22.3 0.24 Amortization expense, after-tax 15.1 0.16 Adjusted net income / EPS $ 58.2 $ 0.63 (1) Per share amounts may not recalculate from figures presented herein due to rounding Three Months Ended June 30, 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income attributable to Avient common shareholders $ 33.6 $ 0.36 Special items, after-tax 21.8 0.24 Amortization expense, after-tax 14.8 0.16 Adjusted net income / EPS $ 70.2 $ 0.76 (1) Per share amounts may not recalculate from figures presented herein due to rounding Year Ended December 31, 2024 Reconciliation to Condensed Consolidated Statements of Income $ EPS(1) Net income attributable to Avient common shareholders $ 169.5 $ 1.84 Special items, after-tax 15.9 0.17 Amortization expense, after-tax 59.5 0.65 Adjusted net income / EPS $ 244.9 $ 2.66 (1) Per share amounts may not recalculate from figures presented herein due to rounding 3 AVNT Q1 2025 webcast slides_v16.pdf Q1 2025 Earnings webcast Slide 1 Slide 2: Disclaimer Slide 3: Q1 2025 highlights Slide 4: Q1 2025 organic revenue growth - by region Slide 5: Playbook in current environment Slide 6 Slide 7: Color, Additives & Inks – Q1 2025 performance Slide 8: Specialty Engineered Materials – Q1 2025 performance Slide 9: Global reach with a local touch Slide 10 Slide 11: 2025 financial guidance unchanged...